GE HealthCare Technologies Inc. (GEHC)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, GE HealthCare Technologies Inc. keeps $11 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 3
in 73 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
GE HealthCare’s third fiscal quarter of 2026 topped consensus on both EPS and revenue, as reported October 28, 2026, with revenue rising 7.2% to about $5.5 billion (up from roughly $5.1 billion a year ago). The quarter’s outperformance showed up in the consensus comparison, with EPS of $1.34 topping the $1.20 estimate (+11.7%) and revenue of $5.513 billion topping the $5.351 billion estimate (+3%). Profitability ran at a gross margin of about 40% and an operating margin near 15%, alongside gross profit of roughly $2.2 billion and operating income of about $804 million. Net income increased 37.7% to around $614 million (from roughly $446 million a year ago), while EPS was up 25.2% from $1.07. The company generated operating cash flow of about $907 million and paid roughly $16 million in dividends during the quarter. Next-period consensus calls for EPS of $1.60 on revenue of $5.919 billion.
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. creates, manufactures, and markets healthcare technology, with shares listed as GEHC on NASDAQ and FY2025 revenue of $20.6 billion. The company sells medical devices, services, and integrated digital solutions that support diagnosis, treatment, and ongoing patient monitoring across imaging, ultrasound, patient care, and diagnostic pharmaceuticals.
Today's Snapshot
The day ended with GEHC 1.5% lower at 80.64, while its sector was flat. GE HealthCare advanced a manganese-based MRI agent to Phase 3 after positive trial data.
Trading Volume
Above 10d avg 3.2M
3.7M
vs S&P 500 Today
Outperforming Market
+1.96%
Updated: November 20, 2026 at 21:17 UTC
GEHC Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$72.30 - $81.82Buy
- RSI (14)56.55Neutral
- Stochastic %K (14, 3, 3)43.18Neutral
- MACD Level (12, 26)2.93Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.